| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Kinesin2; KLC; Klc1; KNS2; KNS2A;;Kinesin light chain 1 |
| WB Predicted band size | 65 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Kinesin light chain 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下为模拟生成的关于KLC1抗体的参考文献示例(非真实文献，仅供格式参考)：
---
1. **文献名称**: *KLC1 Antibody-Based Profiling Reveals Its Role in Cancer Cell Motility*
**作者**: Smith, A. et al.
**摘要**: 研究通过免疫组化及Western blot分析，发现KLC1在乳腺癌细胞中高表达，并与患者预后不良相关。使用KLC1抗体抑制其功能可显著降低细胞迁移能力，提示其作为癌症治疗靶点的潜力。
2. **文献名称**: *KLC1 Interaction with Neurodegenerative Disease-Linked Proteins*
**作者**: Zhang, L. & Tanaka, M.
**摘要**: 该研究利用KLC1抗体进行共免疫沉淀实验，证明KLC1与阿尔茨海默病相关蛋白APP存在直接相互作用，调控神经元内运输通路。敲低KLC1导致轴突运输障碍，提示其在神经退行中的作用。
3. **文献名称**: *Development of a High-Affinity Monoclonal KLC1 Antibody for Diagnostic Applications*
**作者**: Chen, H. et al.
**摘要**: 研究报道了一种新型KLC1单克隆抗体的开发，验证其特异性及在流式细胞术、免疫荧光中的应用，为KLC1相关疾病的临床检测提供了新工具。
4. **文献名称**: *KLC1 Antibody Screening Identifies Dysregulation in Autophagy Pathways*
**作者**: Gupta, R. et al.
**摘要**: 通过KLC1抗体筛选发现，KLC1缺失会干扰自噬小体的微管依赖性运输，导致肝细胞中脂质积累，为代谢疾病机制研究提供了新视角。
---
**备注**：以上为模拟文献，实际文献需通过PubMed、Google Scholar等平台检索(可尝试关键词：KLC1 antibody, kinesin light chain 1. intracellular transport)。
Kinesin Light Chain 1 (KLC1) is a critical subunit of the kinesin-1 motor protein complex, which facilitates microtubule-dependent intracellular transport of organelles, vesicles, and macromolecules. As part of the tetrameric kinesin-1 structure, KLC1 binds to the kinesin heavy chain (KHC) and regulates cargo recognition, motor activity, and interactions with adaptor proteins. It contains conserved tetratricopeptide repeat (TPR) domains that mediate cargo binding and autoinhibitory mechanisms to control motor function. Dysregulation of KLC1 has been implicated in neurodegenerative diseases (e.g., Alzheimer's, Charcot-Marie-Tooth) due to impaired axonal transport, as well as cancers linked to abnormal cell division and metastasis.
KLC1-specific antibodies are essential tools for studying its expression, localization, and interactions in cellular models. They enable applications such as Western blotting, immunofluorescence, co-immunoprecipitation, and pathological analysis of tissue samples. Recent studies using these antibodies have revealed KLC1's role in autophagosome-lysosome fusion, mitochondrial dynamics, and viral trafficking. Commercial antibodies are typically raised against epitopes in the variable N-terminal or conserved TPR regions, with validation emphasizing specificity across isoforms (KLC1-4). Ongoing research focuses on KLC1's post-translational modifications and therapeutic targeting in transport-related disorders.
×
